Mechanism

treatment

comparator

All cause death (0)

All cause death (1)

Coronary death (2)

Coronary event (3)

Adverse events (4)

Cardiovascular death (5)

Revascularization (6)

Long term death (7)

Non fatal MI (8)

stroke (fatal and non fatal) (9)

Death from any cause or hospitalization for any reason (10)

hospitalisation for heart failure (11)

Cough (12)

Sudden death (13)

cardiovascular events (14)

Hypotension (15)

Adverse events leading to treatment discontinuation (16)

angiodema (17)

death or severe congestive heart failure (18)

NYHA class improvement (19)

Hospitalization for any reason (20)

cardiovascular death, MI, stroke (21)

Hyperkalaemia (22)

death or cardiovascular hospitalization (23)

(24)

Cardiovascular death or hospital admission for CHF (25)

Edit

Candesartan

heart failure, in patients with preserved-LVEF heart failure

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	no data
All cause death	no data
Coronary death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Revascularization	no data
Long term death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	no data
Sudden death	no data
cardiovascular events	no data
Hypotension	no data
Adverse events leading to treatment discontinuation	no data
angiodema	no data
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CHARM preserved, 2003	candesartan target dose 32 mg once daily	placebo	patients with NYHA II-IV heart failure and LVEF higher than 40%

Irbesartan

heart failure, in patients with preserved-LVEF heart failure

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.02 [0.88 1.18]	p=1.00	0	4128	1	I-PRESERVE (McMurray),
All cause death	1.02 [0.88 1.18]	p=1.00	0	4128	1	I-PRESERVE (McMurray),
Coronary death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	1.03 [0.86 1.22]	p=1.00	0	4128	1	I-PRESERVE (McMurray),
Revascularization	no data
Long term death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	no data
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	0.96 [0.82 1.14]	p=1.00	0	4128	1	I-PRESERVE (McMurray),
Cough	no data
Sudden death	no data
cardiovascular events	no data
Hypotension	no data
Adverse events leading to treatment discontinuation	no data
angiodema	no data
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	1.02 [0.90 1.15]	p=1.00	0	4128	1	I-PRESERVE (McMurray),
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	0.97 [0.85 1.10]	p=1.00	0	4128	1	I-PRESERVE (McMurray),
	no data
Cardiovascular death or hospital admission for CHF	0.97 [0.84 1.13]	p=1.00	0	4128	1	I-PRESERVE (McMurray),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
I-PRESERVE (McMurray), 2008	ibersatan 300mg daily	placebo	patients with NYHA II, III, or IV heart failure and an ejection fraction of at least 45%

Telmisartan

patients at high risk for cardiovascular events, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.05 [0.90 1.23]	p=1.00	0	5926	1	TRANSCEND,
All cause death	1.05 [0.90 1.23]	p=1.00	0	5926	1	TRANSCEND,
Coronary death	no data
Coronary event	0.79 [0.62 1.02]	p=1.00	0	5926	1	TRANSCEND,
Adverse events	no data
Cardiovascular death	1.02 [0.85 1.24]	p=1.00	0	5926	1	TRANSCEND,
Revascularization	0.90 [0.77 1.05]	p=1.00	0	5926	1	TRANSCEND,
Long term death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	0.83 [0.64 1.07]	p=1.00	0	5926	1	TRANSCEND,
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	0.84 [0.42 1.67]	p=1.00	0	5926	1	TRANSCEND,
Sudden death	no data
cardiovascular events	0.88 [0.76 1.02]	p=1.00	0	5926	1	TRANSCEND,
Hypotension	1.82 [0.99 3.36]	p=1.00	0	5926	1	TRANSCEND,
Adverse events leading to treatment discontinuation	0.91 [0.81 1.03]	p=1.00	0	5926	1	TRANSCEND,
angiodema	0.67 [0.11 4.02]	p=1.00	0	5926	1	TRANSCEND,
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	0.88 [0.76 1.02]	p=1.00	0	5926	1	TRANSCEND,
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
TRANSCEND, 2008	telmisartan 80 mg/day	placebo	high-risk patients intolerant to angiotensin-converting enzyme inhibitors

Telmisartan

patients at high risk for cardiovascular events, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.98 [0.89 1.07]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
All cause death	0.98 [0.89 1.07]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Coronary death	no data
Coronary event	1.07 [0.93 1.23]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Adverse events	no data
Cardiovascular death	1.00 [0.89 1.12]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Revascularization	1.02 [0.94 1.11]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Long term death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	0.91 [0.79 1.06]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	0.26 [0.21 0.33]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
Sudden death	no data
cardiovascular events	0.99 [0.91 1.08]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
Hypotension	1.54 [1.25 1.90]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
Adverse events leading to treatment discontinuation	0.94 [0.87 1.01]	p=1.00	0	17118	1	ONTARGET (telmisartan alone),
angiodema	0.40 [0.19 0.84]	p=0.04	0	17118	1	ONTARGET (telmisartan alone),
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
ONTARGET (telmisartan alone), 2008	telmisartan 80mg daily	ramipril 10 mg daily	patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage

Enalapril

patients at high risk for cardiovascular events, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.30 [0.45 3.76]	p=1.00	0	1328	1	CAMELOT (enalapril),
All cause death	1.30 [0.45 3.76]	p=1.00	0	1328	1	CAMELOT (enalapril),
Coronary death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	2.43 [0.47 12.59]	p=1.00	0	1328	1	CAMELOT (enalapril),
Revascularization	0.90 [0.66 1.21]	p=1.00	0	1328	1	CAMELOT (enalapril),
Long term death	no data
Non fatal MI	0.56 [0.27 1.19]	p=1.00	0	1328	1	CAMELOT (enalapril),
stroke (fatal and non fatal)	0.65 [0.26 1.60]	p=1.00	0	1328	1	CAMELOT (enalapril),
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	no data
Sudden death	no data
cardiovascular events	0.88 [0.67 1.14]	p=1.00	0	1328	1	CAMELOT (enalapril),
Hypotension	no data
Adverse events leading to treatment discontinuation	no data
angiodema	no data
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
CAMELOT (enalapril), 2004	Enalapril 20mg daily	Placebo	patients with angiographically documented CAD (>20% stenosis by coronary angiography) and diastolic blood pressure <100 mm Hg

Perindopril

heart failure, in patients with preserved-LVEF heart failure

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,
All cause death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,
Coronary death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	no data
Revascularization	no data
Long term death	0.90 [0.46 1.75]	p=1.00	0	850	1	PEP CHF,
Non fatal MI	no data
stroke (fatal and non fatal)	no data
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	0.64 [0.41 1.01]	p=1.00	0	850	1	PEP CHF,
Cough	no data
Sudden death	no data
cardiovascular events	no data
Hypotension	no data
Adverse events leading to treatment discontinuation	no data
angiodema	no data
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
PEP CHF, 2006	perindopril, 4 mg/day	placebo	patients aged >=70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease

Perindopril

patients at high risk for cardiovascular events, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.89 [0.77 1.03]	p=1.00	0	12218	1	EUROPA,
All cause death	0.89 [0.77 1.03]	p=1.00	0	12218	1	EUROPA,
Coronary death	no data
Coronary event	0.77 [0.66 0.89]	p=0.04	0	12218	1	EUROPA,
Adverse events	no data
Cardiovascular death	0.86 [0.72 1.04]	p=1.00	0	12218	1	EUROPA,
Revascularization	0.96 [0.85 1.08]	p=1.00	0	12218	1	EUROPA,
Long term death	no data
Non fatal MI	0.78 [0.67 0.91]	p=0.04	0	12218	1	EUROPA,
stroke (fatal and non fatal)	0.96 [0.73 1.27]	p=1.00	0	12218	1	EUROPA,
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	5.06 [3.46 7.41]	p=0.04	0	12218	1	EUROPA,
Sudden death	no data
cardiovascular events	0.81 [0.71 0.92]	p=0.04	0	12218	1	EUROPA,
Hypotension	3.53 [2.06 6.05]	p=0.04	0	12218	1	EUROPA,
Adverse events leading to treatment discontinuation	1.10 [1.01 1.20]	p=0.04	0	12218	1	EUROPA,
angiodema	no data
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
EUROPA, 2003	perindopril 8 mg once daily	placebo	low-risk patients with stable coronary heart disease and no apparent heart failure

Quinapril

patients at high risk for cardiovascular events, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.99 [0.58 1.71]	p=1.00	0	1750	1	QUIET,
All cause death	0.99 [0.58 1.71]	p=1.00	0	1750	1	QUIET,
Coronary death	0.92 [0.42 2.02]	p=1.00	0	1750	1	QUIET,
Coronary event	0.88 [0.59 1.32]	p=1.00	0	1750	1	QUIET,
Adverse events	no data
Cardiovascular death	0.92 [0.43 1.97]	p=1.00	0	1750	1	QUIET,
Revascularization	1.11 [0.83 1.47]	p=1.00	0	1750	1	QUIET,
Long term death	no data
Non fatal MI	0.89 [0.56 1.42]	p=1.00	0	1750	1	QUIET,
stroke (fatal and non fatal)	no data
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	no data
Sudden death	no data
cardiovascular events	0.88 [0.59 1.32]	p=1.00	0	1750	1	QUIET,
Hypotension	no data
Adverse events leading to treatment discontinuation	no data
angiodema	no data
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
QUIET, 2001	Quinapril 20mg one daily	Placebo	patients with angiographic evidence of coronary artery disease without systolic leftventricular dysfunction

Ramipril

patients at high risk for cardiovascular events, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.85 [0.75 0.96]	p=0.04	0	9297	1	HOPE,
All cause death	0.85 [0.75 0.96]	p=0.04	0	9297	1	HOPE,
Coronary death	no data
Coronary event	no data
Adverse events	no data
Cardiovascular death	0.75 [0.64 0.88]	p=0.04	0	9297	1	HOPE,
Revascularization	0.87 [0.78 0.97]	p=0.04	0	9297	1	HOPE,
Long term death	no data
Non fatal MI	0.81 [0.71 0.92]	p=0.04	0	9297	1	HOPE,
stroke (fatal and non fatal)	0.69 [0.56 0.85]	p=0.04	0	9297	1	HOPE,
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	4.01 [3.15 5.10]	p=0.04	0	9297	1	HOPE,
Sudden death	no data
cardiovascular events	0.79 [0.71 0.88]	p=0.04	0	9297	1	HOPE,
Hypotension	1.26 [0.92 1.73]	p=1.00	0	9297	1	HOPE,
Adverse events leading to treatment discontinuation	1.06 [0.97 1.16]	p=1.00	0	9297	1	HOPE,
angiodema	2.43 [1.01 5.87]	p=0.04	0	9297	1	HOPE,
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	0.79 [0.71 0.88]	p=0.04	0	9297	1	HOPE,
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
HOPE, 2000	ramipril 10 mg once per day orally	placebo	high-risk patients (55 years of age or older) with evidence of vascular disease or diabetes plus one other cardiovascular risk factor and who were not known to have a low ejection fraction or heart failure

Ramipril

patients at high risk for cardiovascular events, in all type of patients

vs ramipril

by 175%

by 20%

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.06 [0.97 1.16]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
All cause death	1.06 [0.97 1.16]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
Coronary death	no data
Coronary event	1.07 [0.93 1.23]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
Adverse events	no data
Cardiovascular death	1.04 [0.92 1.17]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
Revascularization	1.04 [0.95 1.13]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
Long term death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	0.93 [0.80 1.07]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	1.10 [0.95 1.27]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
Sudden death	no data
cardiovascular events	1.00 [0.92 1.09]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
Hypotension	2.75 [2.27 3.32]	p=0.04	0	17077	1	ONTARGET (association vs ramipril),
Adverse events leading to treatment discontinuation	1.20 [1.12 1.28]	p=0.04	0	17077	1	ONTARGET (association vs ramipril),
angiodema	0.73 [0.40 1.33]	p=1.00	0	17077	1	ONTARGET (association vs ramipril),
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
ONTARGET (association vs ramipril), 2008	telmisartan 80mg + ramipril 10mg daily	ramipril 10 mg daily	patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage

Ramipril

patients at high risk for cardiovascular events, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.08 [0.99 1.19]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
All cause death	1.08 [0.99 1.19]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
Coronary death	no data
Coronary event	1.00 [0.87 1.15]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
Adverse events	no data
Cardiovascular death	1.04 [0.93 1.17]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
Revascularization	1.01 [0.93 1.10]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
Long term death	no data
Non fatal MI	no data
stroke (fatal and non fatal)	1.02 [0.88 1.18]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	4.23 [3.37 5.32]	p=0.04	0	17044	1	ONTARGET (association vs telmisartan),
Sudden death	no data
cardiovascular events	1.01 [0.93 1.10]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
Hypotension	1.78 [1.51 2.10]	p=0.04	0	17044	1	ONTARGET (association vs telmisartan),
Adverse events leading to treatment discontinuation	1.28 [1.19 1.37]	p=0.04	0	17044	1	ONTARGET (association vs telmisartan),
angiodema	1.81 [0.83 3.92]	p=1.00	0	17044	1	ONTARGET (association vs telmisartan),
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	no data
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
ONTARGET (association vs telmisartan), 2008	telmisartan 80mg + ramipril 10mg daily	telmisartan 80 mg daily	patients patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage

Trandolapril

patients at high risk for cardiovascular events, in all type of patients

vs placebo

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	0.89 [0.76 1.05]	p=1.00	0	8290	1	PEACE,
All cause death	0.89 [0.76 1.05]	p=1.00	0	8290	1	PEACE,
Coronary death	no data
Coronary event	0.97 [0.88 1.08]	p=1.00	0	8290	1	PEACE,
Adverse events	no data
Cardiovascular death	0.95 [0.76 1.20]	p=1.00	0	8290	1	PEACE,
Revascularization	0.92 [0.77 1.09]	p=1.00	0	8290	1	PEACE,
Long term death	no data
Non fatal MI	1.00 [0.83 1.21]	p=1.00	0	8290	1	PEACE,
stroke (fatal and non fatal)	0.77 [0.56 1.05]	p=1.00	0	8290	1	PEACE,
Death from any cause or hospitalization for any reason	no data
hospitalisation for heart failure	no data
Cough	no data
Sudden death	no data
cardiovascular events	0.97 [0.83 1.13]	p=1.00	0	8290	1	PEACE,
Hypotension	no data
Adverse events leading to treatment discontinuation	no data
angiodema	no data
death or severe congestive heart failure	no data
NYHA class improvement	no data
Hospitalization for any reason	no data
cardiovascular death, MI, stroke	0.94 [0.81 1.08]	p=1.00	0	8290	1	PEACE,
Hyperkalaemia	no data
death or cardiovascular hospitalization	no data
	no data
Cardiovascular death or hospital admission for CHF	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Trial	Studied treatment	Control	Patients
PEACE, 2004	Trandolapril at a target dose of 4 mg per day	Placebo	patients with stable coronary artery disease and normal or slightly reduced left ventricular function

inhibition of the renin-angiotensin system (ACEI or ARB)